Cancer remains the second leading cause of death globally, despite the recent explosion of cancer immunotherapeutics that have significantly improved patient outcome for certain tumor types. Reprogramming patient T cells to recognize specific tumor associated antigens using chimeric antigen receptors (CARs) has revolutionized the field of cancer immunotherapy.

Join for free to read